Ferric Carboxymaltose
Active ingredient: Ferric Carboxymaltose
In short: Ferric carboxymaltose injection is indicated for the treatment of: •iron deficiency anemia (IDA) in: oadult and pediatric patients 1 year of age and older who have either intolerance or an unsatisfactory response to oral iron. oadult patients who have non-dialysis dependent chronic kidney disease.
What is Ferric Carboxymaltose used for?
Ferric carboxymaltose injection is indicated for the treatment of:
•iron deficiency anemia (IDA) in:
oadult and pediatric patients 1 year of age and older who have either intolerance or an unsatisfactory response to oral iron.
oadult patients who have non-dialysis dependent chronic kidney disease.
•iron deficiency in adult patients with heart failure and New York Heart Association class II/III to improve exercise capacity.
⚠ Boxed warning (FDA's strongest warning)
•
Ferric carboxymaltose injection can cause severe, prolonged hypophosphatemia associated with serious outcomes, including hospitalization, osteomalacia and fractures requiring clinical intervention .
•
Hypophosphatemia has occurred in patients with normal baseline phosphate levels and without apparent risk factors for hypophosphatemia .
•
Check serum phosphate levels prior to a repeat course of treatment in patients at risk for low serum phosphate and in any patient who receives a repeat course of therapy within three months . Correct pre-existing hypophosphatemia prior to administering ferric carboxymaltose injection .
•
Advise patients receiving ferric carboxymaltose injection about the risk of hypophosphatemia and to report any signs and symptoms of hypophosphatemia (e.g., fatigue, muscle weakness or pain, bone and joint pain, bone fractures)
.
Ferric Carboxymaltose dosage
Check serum phosphate levels prior to a repeat course of treatment in patients at risk for low serum phosphate and in any patient who receives a repeat course of therapy within three months .
Correct pre-existing hypophosphatemia prior to administering ferric carboxymaltose injection .
For patients weighing 50 kg or more, the recommended dosage is:
•Ferric carboxymaltose injection 750 mg intravenously in two doses separated by at least 7 days for a total cumulative dose of 1,500 mg of iron per course.
•In adult patients, ferric carboxymaltose injection 15 mg/kg body weight up to a maximum of 1,000 mg intravenously may be administered as a single-dose per course.
For patients weighing less than 50 kg, the recommended dosage is ferric carboxymaltose injection 15 mg/kg body weight intravenously in two doses separated by at least 7 days per course.
See Table 1 for recommended dosage for treatment of iron deficiency in patients with heart failure and New York Heart Association class II/III to improve exercise capacity.
Weight less than 70 kg | Weight 70 kg or more
Hb (g/dL) | Hb (g/dL)
< 10 | 10 to 14 | > 14 to < 15 | < 10 | 10 to 14 | > 14 to < 15
Day 1 | 1,000 mg | 1,000 mg | 500 mg | 1,000 mg | 1,000 mg | 500 mg
Week 6 | 500 mg | No dose | No dose | 1,000 mg | 500 mg | No dose
Administer a maintenance dose of 500 mg at 12, 24 and 36 weeks if serum ferritin < 100 ng/mL or serum ferritin 100-300 ng/mL with transferrin saturation < 20%. There are no data available to guide dosing beyond 36 weeks or with Hb ≥ 15 g/dL.
Ferric carboxymaltose injection treatment may be repeated if IDA or iron deficiency in heart failure reoccurs.
Administer ferric carboxymaltose intravenously, either as an undiluted slow intravenous push or by infusion. When administered via infusion, dilute up to 1,000 mg of iron in no more than 250 mL of sterile 0.9% sodium chloride injection, USP, such that the concentration of the infusion is not less than 2 mg of iron per mL and administer over at least 15 minutes.
When added to an infusion bag containing 0.9% sodium chloride injection, USP, at concentrations ranging from 2 to 4 mg of iron per mL, ferric carboxymaltose injection solution is physically and chemically stable for 72 hours when stored at room temperature. To maintain stability, do not dilute to concentrations less than 2 mg iron/mL.
Inspect parenteral drug products visually for the absence of particulate matter and discoloration prior to administration. The product contains no preservatives. Each vial of ferric carboxymaltose injection is intended for a single dose.
When administering ferric carboxymaltose injection 500 or 750 mg as a slow intravenous push, give at the rate of approximately 100 mg (2 mL) per minute. …
How to take Ferric Carboxymaltose — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information) and discuss with the patient the etiology of the iron deficiency anemia and the patient’s iron deficiency anemia treatment options.
Symptomatic Hypophosphatemia
Advise patients to report any signs or symptoms of hypophosphatemia such as fatigue, muscle weakness or pain, bone and joint pain, or bone fractures .
Prior History of Reactions to Parenteral Iron Products
Question patients regarding any prior history of reactions to parenteral iron products .
Serious Hypersensitivity Reactions
Advise patients to report any signs and symptoms of hypersensitivity that may develop during and following ferric carboxymaltose administration, such as rash, itching, dizziness, lightheadedness, swelling, and breathing problems .
Pregnancy
Advise pregnant women about the risk of hypersensitivity reactions which may have serious consequences for the fetus. Advise patients who may become pregnant to inform their healthcare provider of a known or suspected pregnancy .
The brands listed are trademarks of their respective owners.
Distributed by:
Mylan Institutional LLC, a Viatris Company
Morgantown, WV 26505 U.S.A. …
Warnings & precautions
Do not take this medicine if: Ferric carboxymaltose injection is contraindicated in patients with a history of hypersensitivity to ferric carboxymaltose or any of its components .
Symptomatic hypophosphatemia, including severe cases, with serious outcomes such as osteomalacia and fractures requiring clinical intervention have occurred in patients treated with ferric carboxymaltose in the post-marketing setting. These cases have occurred after single and multiple doses of ferric carboxymaltose. Risk factors for hypophosphatemia include a history of gastrointestinal disorders associated with malabsorption of fat-soluble vitamins or phosphate, inflammatory bowel disease, concurrent or prior use of medications that affect proximal renal tubular function, hyperparathyroidism, vitamin D deficiency, malnutrition, and hereditary hemorrhagic telangiectasia (HHT or Osler-Weber-Rendu syndrome). However, individuals without apparent risk factors have experienced symptomatic hypophosphatemia. In most cases, hypophosphatemia resolved within three months.
Check serum phosphate levels prior to a repeat course of treatment if the patient is at risk for low serum phosphate or if the patient will receive a repeat course of therapy within three months of the prior course . Correct pre-existing hypophosphatemia prior to administering ferric carboxymaltose. Monitor serum phosphate levels in patients at risk for chronic low serum phosphate. Treat hypophosphatemia as medically indicated.
Consider permanent discontinuation of ferric carboxymaltose for severe symptomatic hypophosphatemia or persistent hypophosphatemia.
Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving ferric carboxymaltose. …
Ferric Carboxymaltose side effects
The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling:
•Symptomatic Hypophosphatemia
•Hypersensitivity Reactions
•Hypertension
•Laboratory Test Alterations
Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in clinical practice.
In two randomized clinical studies [Studies 1 and 2, see Clinical Studies (14)
], a total of 1,775 patients were exposed to ferric carboxymaltose 15 mg/kg body weight up to a maximum single dose of 750 mg of iron on two occasions separated by at least 7 days up to a cumulative dose of 1,500 mg of iron.
Adverse reactions reported by ≥ 1% of treated patients are shown in the following table.
Ferric Carboxymaltose (N = 1,775)% | Pooled Comparators
Includes oral iron and all formulations of IV iron other than ferric carboxymaltose.
(N = 1,783)% | Oral iron(N = 253)%
Nausea | 7.2 | 2 | 1.2
HypertensionInjection site discoloration was also included in the injection site local administration reactions grouped term. Headache includes headache and migraine. Hepatic enzyme increased includes alanine aminotransferase increased and aspartate aminotransferase increased. Dysgeusia includes dysgeusia and ageusia. …
About this medicine
Ferric carboxymaltose, an iron replacement product, is an iron carbohydrate complex with the chemical name of polynuclear iron (III)-hydroxide 4(R)-(poly-(1→4)-O-α-D-glucopyranosyl)-oxy-2(R),3(R),5(R),6-tetrahydroxy-hexanoate. It has a relative molecular weight of approximately 150,000 Da corresponding to the following empirical formula:
[FeOx(OH)y(H2O)z]n [{(C6H10O5)m(C6H12O7)}
l
]k,
where n ≈ 103, m ≈ 8, l ≈ 11, and k ≈ 4
(l represents the mean branching degree of the ligand).
The chemical structure is presented below:
Ferric carboxymaltose injection is a dark brown, sterile, aqueous, isotonic colloidal solution for intravenous injection. Each mL contains 50 mg iron as ferric carboxymaltose in water for injection. Ferric carboxymaltose injection is available in 20 mL single-dose vials. Sodium hydroxide and/or hydrochloric acid may have been added to adjust the pH to 5.0-7.0.
Each mL of ferric carboxymaltose injection contains 4 mg of sodium.
Vial closure is not made with natural rubber latex. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 7f05ab1e-aed4-4f87-b939-2dc9719aa34c. Read the full official label on DailyMed.
Related medicines
Rosuvastatin Semaglutide Hydrochlorothiazide Apixaban Simvastatin Empagliflozin Furosemide Carvedilol